Vaccine breakthrough infections with SARS-CoV-2 Alpha mirror mutations in Delta Plus, Iota, and Omicron
Replication of SARS-CoV-2 in the human population is defined by distributions of mutants that are present at different frequencies within the infected host and can be detected by ultra-deep sequencing techniques. In this study, we examined the SARS-CoV-2 mutant spectra of amplicons from the spike-coding (S-coding) region of 5 nasopharyngeal isolates derived from patients with vaccine breakthrough. Interestingly, all patients became infected with the Alpha variant, but amino acid substitutions that correspond to the Delta Plus, Iota, and Omicron variants were present in the mutant spectra of the resident virus. Deep sequencing analysis of SARS-CoV-2 from patients with vaccine breakthrough revealed a rich reservoir of mutant types and may also identify tolerated substitutions that can be represented in epidemiologically dominant variants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
The Journal of clinical investigation - 132(2022), 9 vom: 02. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martínez-González, Brenda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 03.05.2022 Date Revised 16.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1172/JCI157700 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337900604 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337900604 | ||
| 003 | DE-627 | ||
| 005 | 20231225235451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/JCI157700 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337900604 | ||
| 035 | |a (NLM)35259127 | ||
| 035 | |a (PII)e157700 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martínez-González, Brenda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine breakthrough infections with SARS-CoV-2 Alpha mirror mutations in Delta Plus, Iota, and Omicron |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2022 | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Replication of SARS-CoV-2 in the human population is defined by distributions of mutants that are present at different frequencies within the infected host and can be detected by ultra-deep sequencing techniques. In this study, we examined the SARS-CoV-2 mutant spectra of amplicons from the spike-coding (S-coding) region of 5 nasopharyngeal isolates derived from patients with vaccine breakthrough. Interestingly, all patients became infected with the Alpha variant, but amino acid substitutions that correspond to the Delta Plus, Iota, and Omicron variants were present in the mutant spectra of the resident virus. Deep sequencing analysis of SARS-CoV-2 from patients with vaccine breakthrough revealed a rich reservoir of mutant types and may also identify tolerated substitutions that can be represented in epidemiologically dominant variants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Molecular biology | |
| 650 | 4 | |a Virology | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Vázquez-Sirvent, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a Soria, María E |e verfasserin |4 aut | |
| 700 | 1 | |a Mínguez, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Salar-Vidal, Llanos |e verfasserin |4 aut | |
| 700 | 1 | |a García-Crespo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a de Ávila, Ana I |e verfasserin |4 aut | |
| 700 | 1 | |a Llorens, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Ruiz, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Roblas, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Gadea, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Ayuso, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Ruíz-Hornillos, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Jorge, Concepción |e verfasserin |4 aut | |
| 700 | 1 | |a Domingo, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Perales, Celia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 132(2022), 9 vom: 02. Mai |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2022 |g number:9 |g day:02 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI157700 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2022 |e 9 |b 02 |c 05 | ||